Faries, 2006 - Google Patents
Evaluation of immunotherapy in the treatment of melanomaFaries, 2006
- Document ID
- 2879119699828812649
- Author
- Faries M
- Publication year
- Publication venue
- Surgical Oncology Clinics
External Links
Snippet
Despite a long-standing interest in harnessing the immune system to combat melanoma, some experts believe that ''immunotherapy is the treatment of tomorrowdand always will be.''In some ways this belief is understandable. Research efforts have yielded many …
- 201000001441 melanoma 0 title abstract description 172
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5152—Tumor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells, macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6012—Haptens, e.g. di- or trinitrophenyl (DNP, TNP)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Palucka et al. | Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity | |
| Bergman | Cancer immunotherapies | |
| Belli et al. | Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings | |
| Barve et al. | Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non–small-cell lung cancer | |
| Alexandrescu et al. | Immunotherapy for melanoma: current status and perspectives | |
| Koido et al. | Current immunotherapeutic approaches in pancreatic cancer | |
| Lechleider et al. | Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant | |
| Obara et al. | Phase I clinical trial of cell division associated 1 (CDCA 1) peptide vaccination for castration resistant prostate cancer | |
| Brichard et al. | Cancer immunotherapy targeting tumour-specific antigens: towards a new therapy for minimal residual disease | |
| Sosman et al. | Melacine®: an allogeneic melanoma tumor cell lysate vaccine | |
| Vermeij et al. | Immunological and clinical effects of vaccines targeting p53‐overexpressing malignancies | |
| Faries et al. | Therapeutic Vaccines for Melanoma. | |
| Nakai et al. | Vaccination of Japanese patients with advanced melanoma with peptide, tumor lysate or both peptide and tumor lysate‐pulsed mature, monocyte‐derived dendritic cells | |
| Yoshimoto et al. | Anti-tumor immune responses induced by radiotherapy: A review | |
| Madan et al. | Demystifying immunotherapy in prostate cancer: understanding current and future treatment strategies | |
| Cavalcante et al. | Combining tumor vaccination and oncolytic viral approaches with checkpoint inhibitors: rationale, pre-clinical experience, and current clinical trials in malignant melanoma | |
| Bergman | Veterinary oncology immunotherapies | |
| Pollack et al. | Immune‐BasedTherapies for Sarcoma | |
| Lens | The role of vaccine therapy in the treatment of melanoma | |
| Hirschowitz et al. | Immunotherapy for lung cancer | |
| Kadison et al. | Immunotherapy of malignant melanoma | |
| Schneble et al. | Novel dendritic cell-based vaccination in late stage melanoma | |
| Rangelova et al. | Immunotherapy in pancreatic cancer—an emerging role: a narrative review | |
| Klein et al. | Melanoma vaccines: developments over the past 10 years | |
| Julve et al. | Gene of the month: cancer testis antigen gene 1b (NY-ESO-1) |